{"schema_version":"secwatch.filing_event.v1","accession":"0001826667-25-000018","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.112174+00:00","generated_at":"2026-05-26T12:24:06.907359+00:00","sec_items":["2.03","3.02"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"TriSalus draws $10M under senior secured credit facility; issues warrants for 91,263 shares","bullets":["Closed Second Tranche of $50M credit facility, receiving $10M on Feb 18, 2025.","Loan maturity date is April 30, 2029.","Issued warrants to OrbiMed to purchase 91,263 shares at $5.4787 per share.","Warrants have a 7-year term and contain customary share/price adjustment provisions.","Third Tranche of up to $15M remains available until Dec 31, 2025 subject to revenue conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001826667-25-000018","json":"https://secwatch.observer/filing/0001826667-25-000018.json","markdown":"https://secwatch.observer/filing/0001826667-25-000018.md","text":"https://secwatch.observer/filing/0001826667-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/0001826667-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/tlsi-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T12:24:06.907359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df4f33d048a2c57327ad831adc1e3438e39e2438","claim":"TriSalus Life Sciences, Inc. incurred term loan of $10 million with OrbiMed Royalty & Credit Opportunities IV, LP maturing April 30, 2029.","evidence_excerpt":"y ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, each other lender that may from time to time become a party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the lenders.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000018/0001826667-25-000018-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$10 million"},{"label":"Counterparty","value":"OrbiMed Royalty & Credit Opportunities IV, LP"},{"label":"Maturity","value":"April 30, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}